Bao Zhong Cai

This inventor holds 9 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Sarepta Therapeutics, Inc., Avi Biopharma, Inc.. Active years: 2011-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bao Zhong Cai. Retrieved from https://idiyas.com/inventor/bao-zhong-cai

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 4.2

ph-index = 4

Forward Citations = 184(Granted Patents)

Location History:

Cambridge, MA (US) (2020)
Corvallis, OR (US) (2011 - 2021)

Company Filing History:

8 out of 127

Sarepta Therapeutics, Inc.

Years Active: 2011-2021

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11208655 - Functionally-modified oligonucleotides and subunits thereof (2021-12-28),

2. 10760078 - Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups (2020-09-01),

3. 10344281 - Functionally-modified oligonucleotides and subunits thereof (2019-07-09),

4. 10202602 - Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups (2019-02-12),

5. 9790499 - Functionally-modified oligonucleotides and subunits thereof (2017-10-17),

6. 9469664 - Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups (2016-10-18),

7. 9278987 - Functionally-modified oligonucleotides and subunits thereof (2016-03-08),

8. 8779128 - Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups (2014-07-15),

9. 7943762 - Oligonucleotide analogs having cationic intersubunit linkages (2011-05-17),

Title: The Innovative Mind of Bao Zhong Cai

Introduction

Bao Zhong Cai, based in Corvallis, Oregon, is an accomplished inventor with a remarkable portfolio of nine patents. His inventions primarily focus on advancements in the field of oligonucleotides, contributing significantly to therapeutic applications aimed at treating diseases.

Latest Patents

Cai's latest patents introduce functionally-modified oligonucleotides and their subunits, providing innovative analogues that include modified intersubunit linkages and altered 3' and/or 5'-end groups. These compounds hold the potential for treating diseases that require the inhibition of protein expression or the correction of aberrant mRNA splice products, which can lead to beneficial therapeutic effects. These groundbreaking developments highlight the importance of Cai's research in addressing complex medical challenges.

Career Highlights

Throughout his career, Bao Zhong Cai has made significant contributions while working with notable companies such as Sarepta Therapeutics, Inc. and Avi Biopharma, Inc. His expertise in the field has driven innovations that are paving the way for new therapeutic modalities and enhancing patient care.

Collaborations

Cai has collaborated with other renowned professionals in the industry, including Dwight D. Weller and Gunnar J. Hanson. These collaborations have fostered a productive environment for the development and optimization of his innovative projects, showcasing the importance of teamwork in the invention process.

Conclusion

Bao Zhong Cai exemplifies the spirit of innovation through his unwavering commitment to advancing oligonucleotide research and therapeutics. His contributions not only highlight his inventive prowess but also underscore the significant impact of collaborative efforts in the field of biomedicine. As he continues to innovate, his work will undoubtedly contribute to improving treatment options for various diseases, making him a notable figure in the realm of modern inventions.

Profile summary based on public USPTO records.